Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: A systematic review and meta-analyses

Abstract

Aims

We assessed the clinical characteristics and prognosis of chronic heart failure patients with improved ejection fraction (HFIEF) compared with persistently reduced ejection fraction (HFpREF) after evidence-based therapy.

Methods and results

We performed a meta-analysis including 24 eligible observational studies comparing 2663 HFIEF (≥5% left ventricular ejection fraction (LVEF) improvement) versus 8355 HFpREF patients who received recommended drug therapy, cardiac resynchronization therapy and/or intracardiac defibrillator. LVEF was assessed at baseline and reassessed after 19 ± 19 months. The primary endpoints were all-cause mortality and appropriate shocks. The mean duration of follow-up was 39 ± 12 months. Among HFIEF patients, LVEF improved 16.3 percentage points (95% confidence interval 15.9–16.6, p < 0.0001). Compared with HFpREF patients, HFIEF patients had a comparable mean age (60.9 years vs. 62.4 years, p = 0.11), were more often women (33% vs. 25%), had a higher prevalence of non-ischaemic heart failure (58% vs. 53%), less diabetes (27% vs. 28%), higher systolic blood pressure (127.5 ± 9 vs. 122 ± 12 mmHg) and lower left ventricle end-diastolic diameter (64.1 ± 3.7 vs. 67.4 ± 4.9 mmHg), all p-values < 0.05. Absolute risk of all-cause mortality was lower in HFIEF (5.8%) compared with HFpREF (17.5%) with a risk ratio of 0.34 (95% confidence interval 0.28-0.41), p < 0.001. Risk of appropriate shocks was significantly lower in HFIEF versus HFpREF (risk ratio 0.58 (95% confidence interval 0.46–0.74), p < 0.001).

Conclusion

In heart failure patients, we identified several baseline characteristics in favour of an improved LVEF, in response to evidence based therapy. Patients with improved LVEF had significantly lower risks of mortality and appropriate shocks compared with patients with persistently reduced LVEF.

Keywords

Heart failure ejection fraction improved prognosis

Get full access to this article

View all access options for this article.

References

Braunwald

. Heart failure. JACC Heart Fail 2013; 1: 1–20.

Stevenson

. Heart failure with better ejection fraction: A modern diagnosis. Circulation 2014; 129: 2364–2367.

Kramer

Trikalinos

Kent

et al.

Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: A meta-analytic approach. J Am Coll Cardiol 2010; 56: 392–406.

Punnoose

Givertz

Lewis

et al.

Heart failure with recovered ejection fraction: A distinct clinical entity. J Card Fail 2011; 17: 527–532.

Basuray

French

et al.

Heart failure with recovered ejection fraction: Clinical description, biomarkers, and outcomes. Circulation 2014; 129: 2380–2387.

Yancy

Jessup

Bozkurt

et al.

2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240–e327.

Jaiswal

Nguyen

Carry

et al.

Pharmacologic and endovascular reversal of left ventricular remodeling. J Card Fail 2016 Oct; 22: 829–839.

Naksuk

Saab

et al.

Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fraction. J Card Fail 2013; 19: 426–430.

Cicoira

Zanolla

Latina

et al.

Frequency, prognosis and predictors of improvement of systolic left ventricular function in patients with ‘classical’ clinical diagnosis of idiopathic dilated cardiomyopathy. Eur J Heart Fail 2001; 3: 323–330.

10.

Florea

Rector

Anand

et al.

Heart failure with improved ejection fraction: Clinical characteristics, correlates of recovery, and survival: Results from the Valsartan Heart Failure Trial. Circ Heart Fail 2016; 9: 1–7.

11.

Ruwald

Solomon

Foster

et al.

Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: Results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation 2014; 130: 2278–2286.

12.

Steimle

Stevenson

Fonarow

et al.

Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol 1994; 23: 553–559.

13.

Zhang

Guallar

Blasco-Colmenares

et al.

Changes in follow-up left ventricular ejection fraction associated with outcomes in primary prevention implantable cardioverter-defibrillator and cardiac resynchronization therapy device recipients. J Am Coll Cardiol 2015; 66: 524–531.

14.

Moher

Shamseer

Clarke

et al.

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1–1.

15.

Schaer

Osswald

Di Valentino

et al.

Close connection between improvement in left ventricular function by cardiac resynchronization therapy and the incidence of arrhythmias in cardiac resynchronization therapy-defibrillator patients. Eur J Heart Fail 2010; 12: 1325–1332.

16.

Antonio

Teixeira

Coelho

et al.

Identification of ‘super-responders’ to cardiac resynchronization therapy: The importance of symptom duration and left ventricular geometry. Europace 2009; 11: 343–349.

17.

Cioffi

Stefenelli

Tarantini

et al.

Prevalence, predictors, and prognostic implications of improvement in left ventricular systolic function and clinical status in patients >70 years of age with recently diagnosed systolic heart failure. Am J Cardiol 2003; 92: 166–172.

18.

De Groot

Fertin

Duva

et al.

Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after beta-blocker therapy. Circ Heart Fail 2014; 7: 434–439.

19.

Kim

Lee

et al.

Impact of improved left ventricular systolic function on the recurrence of ventricular arrhythmia in heart failure patients with an implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol 2016; 27: 1191–1198.

20.

Markowitz

Lewen

Wiggenhorn

et al.

Relationship of reverse anatomical remodeling and ventricular arrhythmias after cardiac resynchronization. J Cardiovasc Electrophysiol 2009; 20: 293–298.

21.

Metra

Nodari

Parrinello

et al.

Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: Clinical correlates and prognostic significance. Am Heart J 2003; 145: 292–299.

22.

Rickard

Kumbhani

Popovic

et al.

Characterization of super-response to cardiac resynchronization therapy. Heart Rhythm 2010; 7: 885–889.

23.

Schliamser

Kadish

Subacius

et al.

Significance of follow-up left ventricular ejection fraction measurements in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial (DEFINITE). Heart Rhythm 2013; 10: 838–846.

24.

Steffel

Milosevic

Hurlimann

et al.

Characteristics and long-term outcome of echocardiographic super-responders to cardiac resynchronisation therapy: ‘Real world’ experience from a single tertiary care centre. Heart 2011; 97: 1668–1674.

25.

Trullas

Manzano

Formiga

et al.

Heart failure with recovered ejection fraction in a cohort of elderly patients with chronic heart failure. Cardiology 2016; 135: 196–201.

26.

Van Boven

Bogaard

Ruiter

et al.

Functional response to cardiac resynchronization therapy is associated with improved clinical outcome and absence of appropriate shocks. J Cardiovasc Electrophysiol 2013; 24: 316–322.

27.

Ypenburg

van Bommel

Borleffs

et al.

Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. J Am Coll Cardiol 2009; 53: 483–490.

28.

Zecchin

Proclemer

Magnani

et al.

Long-term outcome of ‘super-responder’ patients to cardiac resynchronization therapy. Europace 2014; 16: 363–371.

29.

Eickholt

Siekiera

Kirmanoglou

et al.

Improvement of left ventricular function under cardiac resynchronization therapy goes along with a reduced incidence of ventricular arrhythmia. PloS One 2012; 7: e48926–e48926.

30.

Garcia-Lunar

Castro-Urda

Toquero-Ramos

et al.

Ventricular arrhythmias in super-responders to cardiac resynchronization therapy. Rev Esp Cardiol (Engl Ed) 2014; 67: 883–889.

31.

Kalogeropoulos

Fonarow

Georgiopoulou

et al.

Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol 2016; 1: 510–518.

32.

Lee

Gona

Albano

et al.

A systematic assessment of causes of death after heart failure onset in the community: Impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail 2011; 4: 36–43.

33.

Merlo

Pyxaras

Pinamonti

et al.

Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 2011; 57: 1468–1476.

34.

Sato

Yoshihisa

Kanno

et al.

Cardiopulmonary exercise testing as prognostic indicators: Comparisons among heart failure patients with reduced, mid-range and preserved ejection fraction. Eur J Prev Cardiol 2017; 24: 1979–1987.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.70 MB